# Baseimmune

> Baseimmune is a London-based biotech that uses a proprietary deep-learning platform to design synthetic antigens - the active ingredients in vaccines and immunotherapies. Founded in 2019 by three researchers who met at Oxford's Jenner Institute, the company originally built AI-designed 'future-proof' vaccine candidates against fast-mutating pathogens such as coronavirus, malaria and African swine fever. In 2026 it extended its computational antigen-design platform beyond infectious disease into chronic conditions, with a lead program targeting idiopathic pulmonary fibrosis. Baseimmune closed an $11.3M (about GBP 9M) Series A in February 2024 led by MSD Global Health Innovation Fund and IQ Capital.

- **Founded:** 2019
- **Headquarters:** London, United Kingdom
- **Founders:** Joshua Blight (Co-Founder & CEO), Ariane Gomes (Co-Founder & Chief Scientific Officer), Phillip Kemlo (Co-Founder & Software/Platform Lead)
- **Team size:** ~28 employees
- **Products:** Antigen Design Platform, Coronavirus vaccine candidate, Malaria vaccine candidate, African swine fever vaccine candidate, Fibrosis / IPF immunotherapy program
- **Notable:** Founders' Oxford vaccine method reached clinical trials faster than any prior candidate at the Jenner Institute., Platform accurately anticipated major COVID-19 variants (including Alpha and Delta) from limited early data., Named a Founders Forum 'Rising Star' in 2022.

## Products & services

- **Antigen Design Platform** — A proprietary deep-learning platform that designs synthetic antigens by combining the pathogen components most likely to trigger broad, protective immune responses, integrating structural modelling and experimental screening.
- **Coronavirus vaccine candidate** — A preclinical, variant-resilient COVID-19 vaccine candidate designed to anticipate viral mutation.
- **Malaria vaccine candidate** — A preclinical vaccine program targeting the malaria parasite, a long-standing hard target in the field.
- **African swine fever vaccine candidate** — A preclinical veterinary/animal-health vaccine candidate against African swine fever virus.
- **Fibrosis / IPF immunotherapy program** — A multi-pathway immunotherapy program applying the antigen-design platform to idiopathic pulmonary fibrosis, with proof-of-concept efficacy readouts expected in 2026-2027.

## Achievements

- Founders' Oxford vaccine method reached clinical trials faster than any prior candidate at the Jenner Institute.
- Platform accurately anticipated major COVID-19 variants (including Alpha and Delta) from limited early data.
- Named a Founders Forum 'Rising Star' in 2022.
- Closed an oversubscribed $11.3M Series A in February 2024 led by MSD Global Health Innovation Fund and IQ Capital.
- Advanced three preclinical vaccine candidates (coronavirus, malaria, African swine fever).
- Extended the platform into chronic disease with a lead IPF fibrosis program in 2026.

## Latest updates

- **2026-03** — Announced strategic expansion into fibrosis with a lead program targeting idiopathic pulmonary fibrosis (IPF); proof-of-concept efficacy readouts expected in 2026-2027.
- **2024-02** — Closed $11.3M (about GBP 9M) Series A led by MSD Global Health Innovation Fund and IQ Capital to accelerate its three preclinical vaccine candidates.
- **2021-10** — Raised $4.8M seed round to build out the antigen-design platform and pipeline.

## Links

- Website: https://www.baseimmune.co.uk
- LinkedIn: https://www.linkedin.com/company/baseimmune
- Twitter/X: https://twitter.com/baseimmune
- Instagram: https://www.instagram.com/baseimmune

---

Profile page: https://yespress.io/baseimmune
Published by YesPress — https://yespress.io
Last updated: 2026-07-22